about
Evaluation of antibody response to Plasmodium falciparum in children according to exposure of Anopheles gambiae s.l or Anopheles funestus vectorsHuman IgG response to a salivary peptide, gSG6-P1, as a new immuno-epidemiological tool for evaluating low-level exposure to Anopheles bitesA trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese childrenEvaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort StudyHuman antibody responses to the Anopheles salivary gSG6-P1 peptide: a novel tool for evaluating the efficacy of ITNs in malaria vector controlThe ADVANCE Code of Conduct for collaborative vaccine studies.Estimation of background incidence rates of Guillain-Barré syndrome in Germany - a retrospective cohort study with electronic healthcare data.Novel peptide marker corresponding to salivary protein gSG6 potentially identifies exposure to Anopheles bites.First attempt to validate the gSG6-P1 salivary peptide as an immuno-epidemiological tool for evaluating human exposure to Anopheles funestus bites.Immunological consequences of intermittent preventive treatment against malaria in Senegalese preschool children.Immunoglobulin G antibody profiles against Anopheles salivary proteins in domestic animals in Senegal.Human antibody response to Anopheles gambiae saliva: an immuno-epidemiological biomarker to evaluate the efficacy of insecticide-treated nets in malaria vector controlNon-specific effects of vaccination on child survival: prospective cohort study in Burkina FasoNon-specific effects of vaccination on child survival? A prospective study in Senegal.High-titer measles vaccination before 9 months of age and increased female mortality: do we have an explanation?An insight into immunogenic salivary proteins of Anopheles gambiae in African children[Nutrition survey in the Republic of the Congo: results from a national survey conducted in 1987]Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries.Perspectives on benefit-risk decision-making in vaccinology: Conference report.Vaccine effects and impact of vaccination programmes in post-licensure studies.Antibody response against saliva antigens of Anopheles gambiae and Aedes aegypti in travellers in tropical Africa.Divergent mortality for male and female recipients of low-titer and high-titer measles vaccines in rural Senegal.Epidemiological impact of vaccination on the dynamics of two childhood diseases in rural Senegal.Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial.Nutritional change and economic crisis in an urban Congolese community.Change in body water distribution index in infants who become stunted between 4 and 18 months of age.Child mortality following standard, medium or high titre measles immunization in West Africa.Glycosylated haemoglobin in children with protein-energy malnutrition.Mothers prolong breastfeeding of undernourished children in rural Senegal.Age at introduction of complementary food and physical growth from 2 to 9 months in rural Senegal.Quantitative benefit-risk assessment by MCDA of the quadrivalent HPV vaccine for preventing anal cancer in males.Large-scale comparative analysis of pertussis population dynamics: periodicity, synchrony, and impact of vaccination.IgE and IgG4 antibody responses to Aedes saliva in African children.[Analysis of evolution of vaccine coverage in Niakhar, a rural area of Senegal, between 1984 and 2003]Sustained High Effectiveness of RotaTeq on Hospitalizations Attributable to Rotavirus-Associated Gastroenteritis During 4 Years in Finland.Comparative safety and immunogenicity of an acellular versus whole-cell pertussis component of diphtheria-tetanus-pertussis vaccines in Senegalese infants.Increased long term mortality associated with rash after early measles vaccination in rural Senegal.Impact and effectiveness of RotaTeq® vaccine based on 3 years of surveillance following introduction of a rotavirus immunization program in Finland.Correction: Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study.Domestic animals as carriers of Bordetella species in Senegal.
P50
Q27481262-29543100-2EBF-4249-986B-45E52744E1A2Q27489414-5D3394C8-CF69-41DF-9927-6FCB0E80A244Q28471975-902A86A6-7144-4188-8426-334432A662D5Q28647510-5E25611B-5D2E-4984-A09A-7F6E38F5FDF3Q28744241-7DE590B3-FF73-4C35-ADA3-A4789283326CQ30235320-D5E22C93-7896-422D-97EF-68D80E75B8F6Q30881458-EBF10CBA-F056-4E9B-9528-7E9D977986CFQ33346270-02E9C0F7-9D67-475E-936A-D10E99BD98F5Q34023538-155F7C86-C01B-4CF7-A3A6-8352A653B404Q34025033-6C6716ED-29C2-4C01-89BF-374BDA044FADQ34027255-44BB862D-BBE5-4FBC-9C6A-F8F89124C254Q34030263-8BB52DB7-3ED1-47E5-9E77-49F2BE9281BEQ34369142-6502E1F9-142D-4B0D-9C2D-F164E9E4AB85Q34453927-07D275DA-743D-4889-9B0B-A1CE92D42271Q35197429-CA6E6E5F-954A-4E02-A034-A7891D9E1878Q35840659-CAE197E1-2430-497E-AAC6-409CD2D7975AQ36669148-D90C2821-03B3-4355-B6BD-8EC584CF1CB3Q36904712-0C18D7F1-B7FD-4DCD-8D16-ADB200D0E7F9Q37130178-36A7D52B-1F5D-47BD-A89D-2A9AD8B8D9CAQ38121682-B52B04BB-9F55-47AD-BD45-4BF95D897DC1Q38573143-ADCA04F5-7150-4E2E-B76A-D6D059B81C04Q38850470-80412CAC-C40B-4196-918B-20E3232D6AFDQ38922565-768162F0-8151-464B-8272-E284B20301C1Q38947658-C6F95695-1B38-4AE4-9333-C5BE10FAD79BQ38953453-B31DD97F-58FF-45CC-A581-31801ED41E75Q39018405-F60F5694-5634-41AB-8FC3-3E875CBCCB43Q39142222-AC40FE94-43E0-46C5-9C07-C02D30FBFF83Q39464994-E32EEC85-8A74-4E9F-BF10-4D7D2907F280Q39465004-9634632C-4CD0-4A09-ADE5-3282D3E6E21AQ39465010-C965A4FA-4D50-48C0-9CFC-B753E1300B34Q40367033-824DD9F5-2C10-432B-8485-FC3298B4E6B0Q40416402-9EF5419B-E567-4679-918C-B204496C6E62Q40439859-D7F2035C-AFBD-4B11-8CE1-63A3B9623221Q40459226-2B20335C-C4CC-4E28-867E-6CACD87A632DQ40530316-54E13353-4FE5-4455-8B7C-897CBA849033Q40660357-CAFB40A4-66CA-4BA6-A680-872CBBACE244Q40825122-CFC5AF96-7462-44E4-BDB8-31046B9EC14FQ42268229-80F2C6DB-F712-4B65-99B4-BD5EE4A85718Q42536439-B8E53E66-C99F-47FE-96EE-D9C56C8B5129Q43220812-C37764CF-23B7-4557-869E-5B31DEB4088A
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
François Simondon
@ast
François Simondon
@en
François Simondon
@es
François Simondon
@nl
François Simondon
@sl
type
label
François Simondon
@ast
François Simondon
@en
François Simondon
@es
François Simondon
@nl
François Simondon
@sl
prefLabel
François Simondon
@ast
François Simondon
@en
François Simondon
@es
François Simondon
@nl
François Simondon
@sl
P106
P21
P31
P496
0000-0003-0395-1314